TB-500 Half-Life: Why the Published Answer Is Still Uncertain
Direct answer: No reliable published human pharmacokinetic study has established a terminal half-life for the seven-residue TB-500 fragment Ac-LKKTETQ. Numbers copied from full-length thymosin beta-4, animal detection studies, or unsourced vendor pages should not be presented as the human half-life of TB-500.
The first problem is identity. In analytical literature, TB-500 was identified as the N-terminally acetylated thymosin beta-4 fragment Ac-LKKTETQ, corresponding to residues 17–23. Full-length thymosin beta-4 contains 43 amino acids. The TB-500 versus thymosin beta-4 guide explains why results for these molecules cannot be merged.
What has actually been published?
The 2012 paper indexed by NIH PubMed (PMID 22962027) synthesized and characterized Ac-LKKTETQ and proposed LC-MS methods for detecting it in plasma and urine. A related equine doping-control study indexed by NIH PubMed (PMID 23084823) focused on analytical detection. These studies are important identity and method records, but they do not provide a validated human terminal half-life.
| Common statement | Evidence status | Better wording |
|---|---|---|
| “TB-500 has a fixed human half-life” | Not established by a published human PK study located for Ac-LKKTETQ | Human terminal half-life remains uncertain |
| “Thymosin beta-4 half-life applies to TB-500” | Molecules differ in sequence length and molecular identity | Keep full-length and fragment data separate |
| “Detection in plasma proves pharmacokinetics” | Detection methods show that an analyte can be measured | PK needs timed concentration data and model fitting |
| “A COA supplies half-life” | COAs describe tested material attributes | Biological disposition requires a separate study |
Why detection is not half-life
An LC-MS method can identify a target signal in a matrix, establish retention and mass transitions, and define a detection window under specified conditions. A half-life calculation needs a concentration-time series, adequate terminal sampling, a quantitative assay, and a stated pharmacokinetic model. Detecting Ac-LKKTETQ in one or more samples does not provide those elements.
Matrix and species also matter. Equine plasma, human plasma, urine, purified enzyme systems, and cell-culture media contain different peptidases and recovery challenges. A value measured in one cannot be moved to another without evidence. General peptide stability principles are useful for designing an experiment, but they do not replace compound-specific data.
Why thymosin beta-4 data cannot fill the gap
Full-length thymosin beta-4 and Ac-LKKTETQ differ in size, sequence context, charge distribution, protease-accessible bonds, and possible interactions. Even if a study measures the disappearance of full-length thymosin beta-4, it does not automatically describe the fragment. The thymosin beta-4 sulfoxide guide adds another identity boundary: oxidation of the full-length protein is not a result for the seven-residue fragment.
A well-designed TB-500 stability or pharmacokinetic study should state the exact analyte, acetylation state, matrix, species, temperature, sampling times, extraction recovery, calibration range, lower limit of quantitation, and terminal-slope method. It should also distinguish intact parent peptide from fragments or metabolites.
The TB-500 research material page identifies the catalog item, while the COA library provides lot-matched analytical records where available. Neither is a human-use claim. Related research materials are grouped in the Recovery Peptides collection, including the BPC-157 and TB-500 blend; a blend requires component-specific interpretation.
The BPC-157 and TB-500 evidence guide shows how to keep nonclinical findings attached to their original molecule, model, and endpoint.
The TB-500 LC-MS detection guide maps parent and metabolite findings by species, specimen, and analytical threshold.
Research limitations
The absence of a located human PK study is not proof that no unpublished data exist. It means a precise public human half-life should not be asserted from the cited analytical literature. Future evidence would need exact Ac-LKKTETQ identity, quantitative timed samples, a defined population, and transparent pharmacokinetic analysis.
Frequently asked questions
What is the half-life of TB-500?
A reliable human terminal half-life for Ac-LKKTETQ has not been established in the cited peer-reviewed literature.
Is TB-500 the same as thymosin beta-4?
No. Analytical studies identify TB-500 as the acetylated 17–23 fragment; thymosin beta-4 is the full 43-residue molecule.
Can an LC-MS detection study calculate half-life?
Only if it includes validated quantitative concentration-time sampling and suitable terminal-phase analysis. Detection alone is insufficient.
Does a product purity result predict half-life?
No. Purity and biological disposition are different measurements.
NEXTWAVE PEPTIDES documents research materials without converting unresolved pharmacokinetic questions into fixed claims.